Rchr
J-GLOBAL ID:201801018946450850   Update date: Sep. 19, 2021

Asada Kiyoshi

Asada Kiyoshi
Affiliation and department:
Job title: 講師
Research field  (2): Molecular biology ,  Internal medicine - General
Research keywords  (4): regulatory science ,  Epigenetics ,  Liver fibrosis ,  Gastroenterology
Papers (39):
  • Ryuichi Noguchi, Kosuke Kaji, Tadashi Namisaki, Kei Moriya, Hideto Kawaratani, Mitsuteru Kitade, Hiroaki Takaya, Yosuke Aihara, Akitoshi Douhara, Kiyoshi Asada, et al. Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. Molecular medicine reports. 2020. 22. 4. 2948-2956
  • Kiyoshi Asada, Kosuke Kaji, Shinya Sato, Kenichiro Seki, Naotaka Shimozato, Hideto Kawaratani, Hiroaki Takaya, Yasuhiko Sawada, Keisuke Nakanishi, Masanori Furukawa, et al. Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2'-deoxycytidine in Hepatic Stellate Cells. Biology. 2020. 9. 6
  • Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, et al. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. Hepatology research : the official journal of the Japan Society of Hepatology. 2019
  • Kenichiro Seki, Mitsuteru Kitade, Norihisa Nishimura, Kosuke Kaji, Kiyoshi Asada, Tadashi Namisaki, Kei Moriya, Hideto Kawaratani, Yasushi Okura, Hiroaki Takaya, et al. Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. Oncotarget. 2018. 9. 47. 28638-28651
  • Yasushi Okura, Tadashi Namisaki, Kei Moriya, Mitsuteru Kitade, Kosuke Takeda, Kosuke Kaji, Ryuichi Noguchi, Norihisa Nishimura, Kenichiro Seki, Hideto Kawaratani, et al. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. HEPATOLOGY RESEARCH. 2017. 47. 12. 1317-1328
more...
MISC (16):
  • 大倉 康志, 浪崎 正, 守屋 圭, 北出 光輝, 竹田 幸祐, 瓦谷 英人, 鍛治 孝祐, 西村 典久, 澤田 保彦, 佐藤 慎哉, et al. アンギオテンシンII受容体拮抗薬およびDPP4阻害薬併用によるNASH肝病態進展抑制効果と作用機序. 日本消化器病学会雑誌. 2017. 114. 臨増総会. A308-A308
  • 西村 典久, 北出 光輝, 浪崎 正, 守屋 圭, 竹田 幸祐, 瓦谷 英人, 大倉 康志, 鍛治 孝祐, 高谷 広章, 佐藤 慎哉, et al. 非環式レチノイドとアンギオテンシンII受容体拮抗薬併用による肝発癌抑制効果とメカニズム. 日本消化器病学会雑誌. 2017. 114. 臨増総会. A319-A319
  • Toshikazu Ushijima, Kiyoshi Asada, Masahiro Maeda, Takeshi Nakajima, Taichi Shimazu. Precision cancer risk diagnosis by accumulation of epigenetic alterations. CANCER RESEARCH. 2016. 76
  • Masahiro Maeda, Kiyoshi Asada, Takeshi Nakajima, Taichi Shimazu, Nobutake Yamamichi, Takao Maekita, Chizu Yokoi, Ichiro Oda, Takayuki Ando, Takeichi Yoshida, et al. Demonstration of the usefulness of an epigenetic cancer risk marker by a multicenter prospective cohort study. CANCER RESEARCH. 2015. 75
  • Genki Mori, Takeshi Nakajima, Ichiro Oda, Kiyoshi Asada, Taichi Shimazu, Nobutake Yamamichi, Takao Maekita, Chizu Yokoi, Mitsuhiro Fujishiro, Takuji Gotoda, et al. Incidence and Risk Factors of Metachronous Gastric Cancer After Endoscopic Resection and Successful Helicobacter pylori Eradication: Results From a Large-Scale, Multicenter Cohort Study in Japan. GASTROINTESTINAL ENDOSCOPY. 2015. 81. 5. AB133-AB133
more...
Work history (6):
  • 2021/04 - 現在 Nara Medical University Institute for Clinical and Translational Science Lecturer
  • 2019/04 - 2021/03 Pharmaceuticals and Medical Devices Agency (PMDA) Office of New Drug I Reviewer
  • 1996 - 2019/03 Nara Medical University Third Department of Internal Medicine Research Scientist
  • 2007 - 2014 国立がん研究センター研究所 エピゲノム解析分野
  • 2003 - 2005 米国オクラホマ医学研究所
Show all
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page